- Policy
- Pfizer’s COVID-19 vaccine needs to be reviewed
- by Kim, Jung-Ju Nov 12, 2020 06:19am
- With the interim results announced that the effectiveness of the COVID-19 vaccine being developed together by Pfizer in the United States and BioNTech in Germany is more than 90% effective, the Korean government has decided to take a cautious approach in the future. It is because the clinical results of other products are expected to be re
- Policy
- The re-evaluation of α-GPC will be implemented next month
- by Lee, Tak-Sun Nov 11, 2020 08:48am
- The MFDS stated that the clinical re-evaluation schedule of the brain function improving drug, Choline alfoscerate has not changed. The clinical plan must be submitted by the 23rd of next month. If the deadline is not met, the sale will be suspended immediately. Shin Seung-seung, an official of the Drug Safety Assessment Division of the
- Company
- GA leads newly appointed at KRPIA and global companies
- by Eo, Yun-Ho Nov 11, 2020 06:10am
- Multinational pharmaceutical companies in South Korea are busy processing a wave of new recruit changes, specifically happening around government affairs jobs. The pharmaceutical industry sources reported many of pharmaceutical companies, as well as Korean Research-based Pharmaceutical Industry Association (KRPIA), have announced a seri
- Company
- A study on Korean patients by Nebilet are released
- by Nov 11, 2020 06:08am
- Menarini Korea (CEO Park Hye-young) presented the results of a BENEFIT subgroup study of Nebilet(Nebivolol, β-blocker) at the 53rd Fall International Conference on the Korean Society of Hypertension (Hypertension Seoul 2020). It was revealed on the 9th. The conference, which was held for two days from the 6th to the 7th, was conducted in
- Product
- Pfizer’s all the items expected to be out of stock?
- by Jung, Heung-Jun Nov 11, 2020 06:08am
- When some local wholesalers sent a text message to the pharmacy saying that all Pfizer items from Pfizer Korea are expected to be sold out, pharmacists are placing large orders to secure stock. The text message the pharmacy received from a wholesaler said that Pfizer stopped placing orders after sales of Pfizer this year, and accordingly,
- Policy
- Yuhan’s no-food-required fenofibrate tablet approved
- by Lee, Tak-Sun Nov 11, 2020 06:07am
- Yuhan Corporation has received the health authority’s approval on a fenofibrate tablet, orally taken regardless of meal consumption, to treat hyperlipidemia. The form and administration method are unique to the drug only in South Korea. GC Pharma with the original fenofibrate Lipidil supra is also in process of developing a tablet with the
- Company
- Viatris separated from Pfizer, officially launched next week
- by Eo, Yun-Ho Nov 10, 2020 05:55pm
- Pfizer's patent expiration division and Mylan’s merger Independent corporation, Viatris, will be officially launched next Monday (16th). According to related industries, in accordance with global measures, Viatris, a Korean subsidiary (currently Pfizer Upjohn Korea), will also be administratively separated from Pfizer and start operating
- Policy
- A tough market for new Rosuzet generic
- by Lee, Tak-Sun Nov 10, 2020 06:06am
- Although the door for generics is to open next year when the post marketing surveillance (PMS) period is terminated for the rosuvastatin and ezetimibe combination drug treating dyslipidemia, the market annually generating 150 billion won is actually not expecting any new generic. Many of pharmaceutical companies have already received the
- Company
- Roche to expand rare disease treatment market presence
- by Eo, Yun-Ho Nov 10, 2020 06:06am
- An anticancer drug powerhouse Roche is consolidating its presence in the rare disease treatment area. In just a week, Roche Korea has won the South Korean health authority’s approval on two new drugs, and it is also bringing another new drug to the Korean market soon. The three new drugs are respectively indicated to treat patients
- Policy
- NA “Age over 65 pneumococcal vaccine should use Prevenar13"
- by Lee, Jeong-Hwan Nov 10, 2020 06:05am
- The National Assembly pointed out the National Immunization Program (NIP) for the pneumococcal vaccine for elderly population aged over 65 should be switched from the existing 23-valent pneumococcal protein polysaccharide vaccine (PPSV23) to 13-valent pneumococcal conjugate vaccine (PCV13). The lawmakers claim the state should provide expens
